Plasmacytoid dendritic cells (pDC) are one of the two main subsets of DC in human blood. They play a major role in anti-viral and autoimmune responses through their unique capacity to produce massive amounts of IFNa in response to both viral and self nucleic acids, respectively, following TLR7 and TLR9 engagement. 1 However, their role in antitumor immunity has not been clarified yet. Emerging evidence indicates that tumor infiltration by pDC may have clinical importance, as underlined by their identification in melanoma, head and neck, lung, ovarian and breast cancers. 1 Ovarian cancer (OC) is the most frequent and aggressive gynecologic cancer. This is due, at least in part, to its diagnosis at advanced stages (III/IV) in the majority of patients with peritoneal carcinosis and malignant ascites. In a recent report, 2 we investigated the clinical significance of the presence of pDC in tumor mass and malignant ascites by conducting a systematic comparison of tumor-associated (TA) and ascites pDC. We observed an accumulation of pDC in most of malignant ascites and their presence at high frequency (highest tertile) in 36% of tumors whereas they were profoundly depleted in blood. Importantly, only accumulation of pDC in tumors was an independent prognostic factor associated with early relapse while their presence in malignant ascites was not deleterious.
These initial results obtained on 33 patients in whom pDC were identified by flow-cytometry as CD4 + TApDC were present in only 18/97 tumors (18%) with a majority (73%) of score +. The median follow-up of the cohort was 34.1 mo. In univariate analysis, the presence of TApDC within cancer epithelium was associated with early relapse, as median progression-free survival (PFS) was estimated to 14.6 mo, compared with 26.2 mo in the absence of TApDC (p = 0.01, Fig. 1D ). Similarly, median overall survival was shorter in the presence of TApDC, although not statistically significant (34.3 mo compared with 67.5 mo, p = 0.09; Fig. 1E ). In multivariate analysis, in addition to clinical prognostic factors (advanced stage, debulking surgery and residual tumor), the presence of TApDC remains an independent prognostic factor associated with shorter PFS (HR = 2.19, 95%IC = 1.1-4.07, p = 0.02).
Interestingly, the presence of TApDC into lymphoid aggregates had no impact on clinical outcome, suggesting a direct interaction between TApDC and tumor cells favoring tumor progression. Thus, using two different and complementary methods (flow-cytometry and IHC) on two independent cohorts, we observed a deleterious impact of the presence of TApDC within tumors on OC patient's outcome. These data corroborate our findings in breast cancer 3 and others in melanoma 4 showing that TApDC accumulation correlates with poor prognosis. Collectively, these results suggest that TApDC may contribute to immune tolerance and tumor progression.
In our initial report in OC, 2 we showed that, unlike ascites pDC, TApDC (1) expressed a semi-mature phenotype as evidenced by high levels of CD40 and CD86 and (2) were strongly affected for their IFNa production in response to CpG-A (TLR9 ligand) known to induce huge amounts of Type I IFNs. The alteration of IFNa production by pDC in response to TLR ligands has been previously described in chronic viral infections such as HIV and HCV contributing to the failure of an efficient immune response. 5 In the context of cancer, previous works have also reported this alteration in breast, 3 lung and head and neck cancers 1 and chronic myeloid leukemia (CML). 6 Type I IFNs promote immunosurveillance through the activation of innate immune cells (reviewed in ref. 7 ) and inhibition of regulatory T cells. 8 The critical role of type I IFNs in anti-tumor immunosurveillance is also well demonstrated in IFNa receptor 1-deficient mice where tumor growth is exacerbated. 7 IFNa has also direct antitumor activities in OC in vitro and in vivo either in nude mice when associated to paclitaxel or in patients with minimal residual tumor 9 by inhibiting OC cell proliferation, tumor growth and angiogenesis. Thus, the inhibition of IFNa production by TApDC in tumor microenvironment might confer a selective advantage for tumor cells allowing their progression.
In addition to altered immunosurveillance function, a direct contribution of pDC to tumor progression has been reported in multiple myeloma (MM) and ovarian cancer. 1 Indeed, pDC in the bone marrow microenvironment promote MM cell growth, survival and drug resistance and pDC isolated from ovarian malignant ascites induce tumor angiogenesis in vivo in immunodeficient mice. 1 In this context, it would be interesting to evaluate the impact of TApDC on tumor cell cycling and angiogenesis in situ in ovarian tumors.
Currently, we assist to a renaissance of IFN therapy for the treatment of myeloid malignancies. Preliminary results of a Phase III clinical trial in CML showed that a pegylated form of IFNa2a (pegIFNa2) in association with imatinib doubled molecular response (30%) in comparison to imatinib alone (14%, p = 0.001). 10 By analogy to CML, the association of pegIFNa2a to chemotherapy could improve outcome in OC. Thus, restoring pDC capacity to produce Type I IFNs represents an attractive therapeutic strategy in cancer. In this context, the treatment of skin cancers with imiquimod (TLR7 ligand) resulted in IFNa production by TApDC that correlates to local immune reaction and destruction of tumor lesions. 1 
